MedPath

he Safety Research of Timing of the Removal of Abdominal Drains After Pancreatic Surgery

Not yet recruiting
Conditions
Safety Issues
Registration Number
NCT04892615
Lead Sponsor
Xian-Jun Yu
Brief Summary

Randomized, open, single-center, controlled prospective studies were designed to obtain reliable level I evidence in evidence-based medicine.Based on the premise of at least a 6-fold reduction in pancreatic fistula, as observed by Kawai et al after early drainage.Considering the overall incidence of pancreatic fistula after standard pancreatectomy at our center (approximately 20%), we would expect this complication to occur in approximately 3.4% of cases in Group A.α was set as 0.05 and β was set as 0.2 (efficacy was 80%), indicating that the total number of study subjects was at least 114 patients (at least 57 patients in the experimental group and 57 patients in the control group).

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
114
Inclusion Criteria
  • ECOG 0-2;
  • The amylase value in the drainage tube of patients receiving pancreaticoduodenectomy or distal pancreatectomy was lower than 5000 IU/L on the first day after surgery;
  • postoperative drainage tube placement;
  • Patients with no obvious contraindication to surgery;
  • Expected postoperative survival ≥3 months;
Exclusion Criteria
  • Pancreaticoduodenectomy and pancreaticogastric anastomosis were performed;
  • Suspicion or abdominal bleeding within 5 days after surgery;
  • suspected biliary and intestinal fistula within 5 days after operation;
  • On the fifth day after the operation, abdominal CT reexamination showed local effusion with a depth greater than 3cm.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of postoperative pancreatic fistula and abdominal infection;3month
Severity of complications (duration of postoperative hospital stay) was assessed by Dindo Clavien classification.3month
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Xianjun Fudan Yu

🇨🇳

Shanghai, Sahnghai, China

Xianjun Fudan Yu
🇨🇳Shanghai, Sahnghai, China
Xianjun F Yu
Contact
18019112906
yuxianjun@fudanpci.org

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.